|
NL-201
NL-201 was an immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients. It is a ''de novo'' protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington. In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201. History The predecessor of NL-201, neoleukin-2/15, was first described and published on ''Nature'' magazine in January 2019. The citizen science distributed computing project Rosetta@home, based at the University of Washington, contributed with "forward folding" experiments that helped validate protein designs of neoleukin-2/15, from which NL-201 was further developed by Neoleukin Therapeutics, a biopharmaceutical company that originated at the IPD. The Phase 1 human clinical trial began on May 5, 2021. In January 2022, Neoleukin Therapeutics announced a collaboration with Merck for a combination clinical trial of Merck's Pembrolizumab ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Rosetta@home
Rosetta@home is a volunteer computing project researching protein structure prediction on the Berkeley Open Infrastructure for Network Computing (BOINC) platform, run by the Baker laboratory at the University of Washington. Rosetta@home aims to predict protein–protein docking and design new proteins with the help of about fifty-five thousand active volunteered computers processing at over 487,946 GigaFLOPS on average as of September 19, 2020. Foldit, a Rosetta@home videogame, aims to reach these goals with a crowdsourcing approach. Though much of the project is oriented toward basic research to improve the accuracy and robustness of proteomics methods, Rosetta@home also does applied research on malaria, Alzheimer's disease, and other pathologies. Like all BOINC projects, Rosetta@home uses idle computer processing resources from volunteers' computers to perform calculations on individual workunits. Completed results are sent to a central project server where they are vali ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pembrolizumab
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein. Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin (pruritus), diarrhea, nausea, rash, fever (pyrexia), cough, difficulty breathing (dyspnea), constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It works by targeting the cellular pathway of proteins found on the body's immune cells and some cancer cells, known as PD-1/PD-L1. Pembrolizumab was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) app ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
